Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
These Cold and Flu Medicines Contain Phenylephrine, the Ingredient the FDA Plans to Ban
Phenylephrine is a medication that’s been used to relieve nasal congestion caused by colds, allergies, and hay fever, per the U.S. National Library of Medicine.
FDA proposes removing ineffective decongestant found in most cold medicine
The Food and Drug Administration (FDA) is proposing the removal from the market of a common ingredient found in most oral over-the-counter cold medicines because it doesn’t work.
FDA Wants To Pull Popular OTC Decongestant Used For Common Cold Over Effectiveness Concerns
On Thursday, the FDA proposed removing oral phenylephrine from the list of approved active ingredients for over-the-counter (OTC) nasal decongestants, citing concerns over its effectiveness. After reviewing available data,
FDA to Finally Ban Controversial Ingredient in Popular Decongestants
These popular brand names appear on oral decongestants that are staples of the cold and flu aisle in American drug stores, and yet many contain an ingredient that does not work as promised. The US Food and Drug Administration (FDA) has now proposed an order to remove oral phenylephrine from every single cold,
Does Phenylephrine Work? Effective Alternatives as FDA Moves to Ban Ingredient in OTC Decongestants
Common decongestants may soon be pulled from shelves. The Food and Drug Administration (FDA) announced Wednesday its proposal to halt use of oral phenylephrine, an ingredient found in many cough and cold medicines,
These Cold & Flu Medicines Contain an Ingredient the FDA Plans to Ban
The FDA proposed a ban on phenylephrine, a common decongestant found in cold and cough medications. Here’s why and a list of medicines with phenylephrine.
FiercePharma
2d
FDA rejects Intercept's ask for Ocaliva full nod in rare liver disease, but accelerated approval remains
In the wake of an unfavorable advisory committee meeting in September, Intercept Pharmaceuticals’ bid to win full approval ...
6d
FDA moves to pull popular decongestant from shelves amid effectiveness concerns
The US Food and Drug Administration announced a proposal to remove oral phenylephrine – a common ingredient in many popular ...
1d
About 100 decongestant lawsuits claiming bogus ingredient tossed
A New York federal judge on Tuesday dismissed about 100 lawsuits that claimed Procter & Gamble , Haleon and other companies ...
MedPage Today
2d
FDA Rejects Full Approval of Liver Disease Drug
said during the
advisory
committee meeting in September. "Design a real study, do a real study, then we can talk about the ...
FiercePharma
13d
In FDA adcomm, Lexicon gets another thumbs down for type 1 diabetes hopeful Zynquista
On Halloween, Lexicon was haunted again as an FDA advisory committee voted 11-3 to reject Zynquista as an accompanying ...
JD Supra
1d
Inaugural Meeting for FDA's Digital Health Advisory Committee to Focus on GenAI-enabled Medical Devices
The U.S. Food and Drug Administration's ("FDA") new advisory committee on digital health is set to examine its approach for evaluating and ...
BioSpace
13d
Lexicon Loses FDA Adcomm Vote on Insulin Adjunct for Patients With Type 1 Diabetes
While an FDA advisory committee saw signals of efficacy for Lexicon Pharmaceuticals’ sotagliflozin, the panel of external ...
The Pharma Letter
2d
FDA slaps CRL on Ocaliva sNDA
Intercept Pharmaceuticals, now wholly owned subsidiary of Italy’s Alfasigma, today revealed that the US Food and Drug ...
1d
Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
Announced Exclusive Licensing Agreement with Viatris for Sotagliflozin in all Markets Outside of the U.S. and EuropeCompleted ZYNQUISTA™ FDA ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback